Sylvie van der Werf Selected Research

COVID-19

3/2024	Incidence of COVID-19 mRNA vaccine symptomatic breakthrough infections during Omicron circulation in adults with or without infection prior to vaccination.
6/2023	Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 in a non-human primate model.
1/2022	Rapidly adapting primary care sentinel surveillance across seven countries in Europe for COVID-19 in the first half of 2020: strengths, challenges, and lessons learned.
1/2022	A virus-derived microRNA targets immune response genes during SARS-CoV-2 infection.
1/2022	Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2.
1/2022	Characterization of SARS-CoV-2 Evasion: Interferon Pathway and Therapeutic Options.
1/2022	Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates.
12/2021	Nasopharyngeal and serological anti SARS-CoV-2 IgG/IgA responses in COVID-19 patients.
9/2021	Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France.
1/2021	Performing point-of-care molecular testing for SARS-CoV-2 with RNA extraction and isothermal amplification.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sylvie van der Werf Research Topics

Disease

33	Human Influenza (Influenza) 01/2023 - 05/2001
27	Infections 03/2024 - 07/2001
14	COVID-19 03/2024 - 01/2020
3	Virus Diseases (Viral Diseases) 01/2021 - 07/2001
3	Pneumonia (Pneumonitis) 01/2020 - 01/2007
2	Coronavirus Infections 01/2021 - 12/2020
2	Respiratory Tract Infections (Respiratory Tract Infection) 08/2013 - 01/2009
2	Influenza in Birds (Avian Flu) 02/2009 - 01/2008
1	Breakthrough Infections 03/2024
1	Coinfection 01/2023
1	RNA Virus Infections 07/2022
1	Porcine Reproductive and Respiratory Syndrome (PRRS) 07/2022
1	Clinical Deterioration 01/2022
1	Lymphopenia (Lymphocytopenia) 10/2021
1	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/2020
1	Viremia 05/2014
1	Pneumococcal Meningitis (Streptococcus pneumoniae Meningitis) 08/2013
1	Pneumococcal Infections 08/2013
1	Bacterial Meningitis 08/2013
1	Respiratory Insufficiency (Respiratory Failure) 06/2013
1	Weight Loss (Weight Reduction) 08/2011
1	Tetanus 05/2010
1	Hepatocellular Carcinoma (Hepatoma) 08/2008
1	Neoplasms (Cancer) 08/2008
1	Severe Acute Respiratory Syndrome 07/2007
1	Superinfection 05/2003

Drug/Important Bio-Agent (IBA)

19	VaccinesIBA 01/2023 - 07/2001
9	AntibodiesIBA 01/2023 - 01/2009
7	Influenza Vaccines (Influenza Vaccine)FDA Link 01/2023 - 05/2010
7	Antiviral Agents (Antivirals)IBA 07/2022 - 01/2019
5	Viral RNAIBA 01/2023 - 05/2001
5	Proteins (Proteins, Gene)FDA Link 10/2020 - 07/2007
4	Neuraminidase (Sialidase)IBA 01/2020 - 12/2009
3	Neutralizing AntibodiesIBA 01/2024 - 05/2010
3	CytokinesIBA 01/2022 - 05/2010
3	RNA (Ribonucleic Acid)IBA 12/2020 - 07/2001
3	Oseltamivir (Tamiflu)FDA Link 01/2020 - 11/2010
3	Hemagglutinins (Hemagglutinin)IBA 05/2014 - 12/2009
3	Zanamivir (Relenza)FDA Link 01/2012 - 01/2007
2	mRNA VaccinesIBA 03/2024 - 09/2021
2	COVID-19 VaccinesIBA 03/2024 - 09/2021
2	Immunoglobulin G (IgG)IBA 01/2024 - 12/2021
2	Monoclonal AntibodiesIBA 06/2023 - 01/2022
2	CI 22IBA 01/2023 - 10/2017
2	Immunoglobulin A (IgA)IBA 01/2022 - 12/2021
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2019 - 08/2013
2	Complement System Proteins (Complement)IBA 01/2012 - 01/2009
2	AntigensIBA 04/2011 - 07/2001
2	NucleoproteinsIBA 02/2009 - 07/2001
2	RibonucleoproteinsIBA 01/2008 - 06/2007
1	N-(2-cyanoethylene)urea (BA 1)IBA 03/2024
1	BNT162 VaccineIBA 03/2024
1	Biomarkers (Surrogate Marker)IBA 03/2024
1	Anti-Idiotypic AntibodiesIBA 01/2024
1	RNA Polymerase IIIIBA 07/2022
1	LigandsIBA 07/2022
1	Pattern Recognition ReceptorsIBA 07/2022
1	Glycoproteins (Glycoprotein)IBA 01/2022
1	MicroRNAs (MicroRNA)IBA 01/2022
1	Apolipoprotein A-I (Apolipoprotein A1)IBA 01/2022
1	Protein Isoforms (Isoforms)IBA 01/2022
1	favipiravirIBA 01/2022
1	InterferonsIBA 01/2022
1	SARS-CoV-2 spike proteinIBA 01/2022
1	HaptoglobinsIBA 01/2022
1	COVA1-18IBA 10/2021
1	Messenger RNA (mRNA)IBA 09/2021
1	Nucleic AcidsIBA 01/2021
1	NanovaccinesIBA 01/2021
1	Histones (Histone)IBA 10/2020
1	RNA Precursors (Precursor, mRNA)IBA 10/2020
1	Ligases (Synthetase)IBA 01/2020
1	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 01/2020
1	Viral ProteinsIBA 01/2020
1	UbiquitinIBA 01/2020
1	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 01/2020
1	1- (3,4- dihydroxyphenyl)- 2- (3- (4- carbamylphenyl)- 1- methylpropylamino)ethanolIBA 01/2019
1	AntipyreticsIBA 11/2017
1	Indicators and Reagents (Reagents)IBA 11/2017
1	Antigen-Antibody Complex (Immune Complex)IBA 05/2014
1	ElementsIBA 03/2012
1	Interleukin-12 (IL 12)IBA 08/2011
1	Interleukin-2 (IL2)IBA 08/2011
1	Liposomes (Liposome)IBA 08/2011
1	Sialic AcidsIBA 01/2011
1	RNA Polymerase II (RNA Polymerase B)IBA 02/2009
1	Peptides (Polypeptides)IBA 08/2008
1	DNA VaccinesIBA 07/2007
1	RNA Polymerase I (Polymerase I, RNA)IBA 06/2007
1	Interferon-gamma (Interferon, gamma)IBA 05/2003
1	Virulence Factors (Pathogenicity Factors)IBA 05/2003
1	Interleukin-10 (Interleukin 10)IBA 05/2003
1	Capsules (Microcapsules)IBA 05/2003

Therapy/Procedure

3	Artificial Respiration (Mechanical Ventilation) 05/2014 - 01/2009
2	Therapeutics 01/2022 - 01/2007
1	Personal Protective Equipment 01/2021
1	Ambulatory Care (Outpatient Care) 01/2021
1	Extracorporeal Membrane Oxygenation 06/2013
1	Immunotherapy 08/2008
1	Aftercare (After-Treatment) 01/2007